Earnings Feed
Start Free
KORU Medical Systems, Inc.·4

Mar 18, 4:45 PM ET

Adams Thomas Edward 4

Research Summary

AI-generated summary

Updated

KORU Medical (KRMD) CFO Thomas Adams Exercises Options, Receives RSUs

What Happened

  • Thomas E. Adams, Chief Financial Officer of KORU Medical Systems (KRMD), reported exercising/converting a derivative to acquire 5,404 shares on March 16, 2026. On the same date 2,123 shares were withheld/disposed to satisfy tax obligations (reported value $9,086 at $4.28 per share). On March 17, 2026 he was granted three restricted stock unit (RSU) awards totaling 136,326 units (38,918 + 38,918 + 58,490), reported as acquisitions at $0.00 (derivative/award).

Key Details

  • Transaction dates/prices:
    • 2026-03-16: Exercise/conversion of derivative — 5,404 shares acquired at $0.00 (M).
    • 2026-03-16: Shares withheld to satisfy tax obligations — 2,123 shares disposed at $4.28 each, total $9,086 (F).
    • 2026-03-17: Three RSU grants totaling 136,326 units (A), recorded at $0.00 (derivative awards).
  • Net immediate effect reported: +5,404 shares acquired, -2,123 shares withheld for taxes → net +3,281 shares added immediately; plus 136,326 RSUs granted (contingent).
  • Shares owned after the transaction: not specified in the filing.
  • Notable footnotes:
    • F1/F3: Each RSU represents a contingent right to one share on vesting.
    • F2: Shares were withheld to satisfy tax obligations upon vesting.
    • F4: One RSU award vests in equal increments beginning March 17, 2027 (time-based).
    • F5: One award vests based on performance through Dec 31, 2028 (payout 0%–150% of target; 100% on a change in control).
    • Awards granted under the Issuer’s 2024 Omnibus Equity Incentive Plan.
  • Filing timeliness: no late filing flag shown in the summary provided.

Context

  • The March 16 action is an exercise/conversion of a derivative (reported as M). The 2,123-share disposition is tax withholding (code F), which is a routine administrative step and not an open-market sale.
  • The March 17 entries are RSU grants (not immediate open-market purchases)—these are contingent awards that vest per the stated schedules and performance conditions, so they do not represent immediately marketable common shares.
  • The filing includes a standard remark that the statement should not be construed as admission of beneficial ownership for Section 16 purposes.